China License Out

Announced Date: 2025-06-26 (June 26, 2025) Asset Name: 9MW3811 Licensor: Mabwell (Shanghai) Bioscience (China) Licensee (Buyer): … [China BD 2025] Mabwell Bioscience and Calico Life Sciences Enters a 596 million USD License for IL-11 Targeting Monoclonal Antibody 9MW3811Read more

Announced Date: 2025-06-22 (June 22, 2025) Asset Name: HBM7020 Licensor (Seller): Harbour BioMed (China) Licensee (Buyer): … [China BD 2025] Harbour BioMed and Otsuka enters a 670 million USD License on BCMAxCD3 bispecific T-cell engager HBM7020Read more

Announced Date: 2025-06-03 (June 3, 2025) Asset Name: ITG-1052 (Lenamilast) Licensor: Suzhou Intragrand Pharma (China) Licensee … [China BD 2025] Intragrand and Transpire enters a license on PDE4 inhibitor ITG-1052Read more

Announced Date: 2025-06-02 (June 2, 2024) Asset Name: HS-20094 Licensor: Hansoh (Hansoh Pharmaceuticals Group, China) Licensee … [China BD deal 2025]Hansoh and Regeneron enters a 2 billion USD license on GLP-1/GIP Ra HS-20094Read more

Announced Date: 2025-05-29 (May 29, 2025) Asset Name: XNW27011 Licensor: Evopoint (Evopoint Biosciences Co., Ltd., China) Licensee … [China BD 2025] Evopoint and Astellas enters a 1.54 billion USD license on CLDN18.2 ADC XNW27011Read more

Announced Date: 2025-04-18 (April 18, 2025) Asset Name: VBS-102 Licensor: VelaVigo Bio (China) Licensee (Buyer): Ollin … [China BD 2025] VelaVigo and Ollin Biosciences Enters a 440 million USD License on IGF-1R/TSHR BsAbs VBS-102Read more

Announced Date: 2025-03-26 (March 26, 2025) Asset Name: PH020 (BAY 3713372) Licensor: Suzhou Puhe BioPharma (China) Licensee … [China BD 2025] Puhe BioPharma and AstraZeneca enters a 2 billion USD license on PRMT5i PH020 (BAY 3713372)Read more

Announced Date: 2025-03-25 (March 25, 2025) Asset Name: HRS-5346 Licensor: Hengrui Pharma (Jiangsu Hengrui Pharmaceuticals Co., … [China BD 2025] Hengrui and MSD enters a 2 billion USD license for oral Lpa inhibitor HRS-5346Read more

Announced Date: 2025-03-24 (March 24, 2025) Asset Name: UBT251 Licensor: United Laboratories (The United Laboratories International … [China BD Deal] TUL and Novo Nordisk enters a 2 billion USD license for UBT251, a GLP-1/GIP/glucagon triple receptor agonistRead more